Live Earnings Conference Call: BioLife Solutions will host a live Q1 2026 earnings call on May 7, 2026 at 4:30PM ET. Get details.

BioLife Solutions (BLFS) Financials

$21.75 +0.20 (+0.93%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$21.75 0.00 (0.00%)

As of 05:30 AM Eastern

Compare

Annual Income Statements for BioLife Solutions

This table shows BioLife Solutions' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-4.21	-6.88	-2.73	-25	-1.66	1.98	-8.91	-140	-68	-20	-4.60
Consolidated Net Income / (Loss)	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	-140	-68	-20	-4.60
Net Income / (Loss) Continuing Operations	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	0.39	-12	-8.79	-12
Total Pre-Tax Income	-5.00	-8.04	-2.52	-25	-3.20	-1.28	-29	-4.85	-12	-8.82	-12
Total Operating Income	-5.02	-4.85	-1.06	3.66	-0.22	-6.24	-35	-5.92	-17	-4.48	-17
Total Gross Profit	3.81	4.78	6.75	14	19	27	37	47	41	50	62
Total Revenue	6.45	8.23	11	20	27	48	119	76	68	75	96
Operating Revenue	6.45	8.23	11	20	27	48	119	76	68	75	96
Total Cost of Revenue	2.63	3.45	4.28	6.22	8.76	21	82	29	27	25	34
Operating Cost of Revenue	2.63	3.45	4.28	6.22	8.76	21	82	29	27	25	34
Total Operating Expenses	8.83	9.63	7.80	9.86	19	34	72	53	59	55	79
Selling, General & Admin Expense	4.87	4.59	4.52	5.95	8.89	15	34	33	43	41	46
Marketing Expense	2.58	3.01	2.09	2.62	4.70	6.41	14	12	11	8.93	9.85
Research & Development Expense	1.38	2.03	1.19	1.30	3.17	6.72	12	8.67	5.52	4.75	7.57
Amortization Expense	-	-	-	0.00	1.08	3.03	8.20	3.99	1.03	0.26	0.26
Other Operating Expenses / (Income)	-	-	-	-	-	-	-	-	0.00	0.00	16
Other Special Charges / (Income)	-	-	-	0.00	0.05	1.58	2.88	-4.75	-2.19	0.00	0.00
Total Other Income / (Expense), net	0.02	-3.19	-1.46	-29	-2.98	4.96	6.13	1.08	4.98	-4.35	4.52
Interest & Investment Income	0.00	-2.79	-1.01	-0.39	9.87	1.36	5.97	0.41	-1.41	-4.84	2.71
Other Income / (Expense), net	0.02	0.00	-0.11	-28	13	3.60	0.17	0.66	6.39	0.49	1.82
Income Tax Expense	-	-	0.00	0.00	-1.54	-3.26	-20	-5.24	-0.06	-0.04	0.05
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	-140	-56	-11	7.54
Basic Earnings per Share	($0.35)	($0.54)	($0.21)	($1.56)	($0.09)	$0.07	($0.23)	($3.29)	($1.55)	($0.44)	($0.09)
Weighted Average Basic Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.50M	42.48M	43.72M	46.07M	47.75M
Diluted Earnings per Share	($0.35)	($0.54)	($0.21)	($1.56)	($0.09)	($0.06)	($0.23)	($3.25)	($1.55)	($0.44)	($0.10)
Weighted Average Diluted Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.50M	43.07M	43.72M	46.07M	48.65M
Weighted Average Basic & Diluted Shares Outstanding	12.18M	12.64M	13.26M	16.26M	19.46M	27.31M	38.50M	43.21M	45.30M	47M	48.30M

This table shows BioLife Solutions' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-10	-29	-15	-10	-21	-1.70	12	-0.45	-16	0.62	11
Consolidated Net Income / (Loss)	-10	-29	-15	-10	-21	-1.70	12	-0.45	-16	0.62	11
Net Income / (Loss) Continuing Operations	-5.52	-16	17	-3.20	-5.56	-0.47	7.68	-0.45	-16	0.62	3.54
Total Pre-Tax Income	-5.52	-16	16	-3.18	-5.56	-0.55	7.54	-0.43	-16	0.70	3.36
Total Operating Income	-11	-15	16	-3.30	-1.31	-0.42	7.35	-1.22	-17	-0.09	1.35
Total Gross Profit	11	12	8.88	12	13	14	9.92	16	16	18	12
Total Revenue	29	24	-15	18	20	21	-8.37	24	25	28	19
Operating Revenue	29	24	-15	18	20	21	-8.37	24	25	28	19
Total Cost of Revenue	18	12	-24	6.19	6.51	7.40	-18	8.16	8.99	10	6.81
Operating Cost of Revenue	18	12	-24	6.19	6.51	7.40	-18	8.16	8.99	10	6.81
Total Operating Expenses	22	27	-7.39	16	15	14	2.57	17	33	18	11
Selling, General & Admin Expense	14	11	4.07	10	9.32	9.33	5.36	12	11	12	11
Marketing Expense	3.83	4.88	-2.47	2.38	2.48	2.51	-2.51	2.60	2.73	2.53	1.99
Research & Development Expense	3.79	3.74	0.39	2.08	2.03	1.89	-0.05	2.20	2.72	2.71	-0.07
Amortization Expense	1.41	1.31	-0.66	0.69	0.68	0.68	0.00	0.70	0.71	0.70	-1.85
Total Other Income / (Expense), net	5.11	-0.21	0.09	0.11	-4.25	-0.13	0.19	0.78	0.93	0.79	2.01
Interest & Investment Income	-0.39	-0.45	-0.20	-0.14	-4.40	-0.23	0.12	0.68	0.68	0.51	0.83
Other Income / (Expense), net	5.50	0.24	0.29	0.25	0.15	0.10	0.07	0.10	0.25	0.28	1.18
Income Tax Expense	0.00	0.12	-0.23	0.02	0.00	-0.08	-0.14	0.01	0.13	0.08	-0.17
Net Income / (Loss) Discontinued Operations	-4.68	-13	-	-7.02	-15	-1.23	-	0.00	0.00	0.00	7.54
Basic Earnings per Share	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27	($0.01)	($0.33)	$0.01	$0.24
Weighted Average Basic Shares Outstanding	43.44M	14.44M	43.72M	35.21M	25.29M	46.18M	46.07M	46.69M	31.96M	47.93M	47.75M
Diluted Earnings per Share	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27	($0.01)	($0.33)	$0.01	$0.23
Weighted Average Diluted Shares Outstanding	43.44M	43.57M	43.72M	45.43M	25.29M	46.18M	46.07M	47.13M	31.96M	48.72M	48.65M
Weighted Average Basic & Diluted Shares Outstanding	43.49M	44.03M	45.30M	46.03M	46.14M	46.39M	47M	47.56M	47.91M	48.15M	48.30M

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.37	-0.77	5.26	24	-15	84	-21	-50	16	60	-62
Net Cash From Operating Activities	-4.97	-4.33	0.61	2.35	1.21	6.65	-4.59	-8.49	-12	8.43	20
Net Cash From Continuing Operating Activities	-4.97	-4.33	0.61	2.35	11	6.65	-4.59	-8.49	-12	8.43	20
Net Income / (Loss) Continuing Operations	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	-140	-68	-20	-4.60
Consolidated Net Income / (Loss)	-5.00	-8.04	-2.52	-25	-1.66	1.98	-8.91	-140	-68	-20	-4.60
Depreciation Expense	0.34	0.37	0.34	0.34	0.72	2.04	4.66	6.78	7.11	5.16	2.25
Amortization Expense	-0.04	0.09	0.03	0.00	1.08	3.03	8.32	9.27	3.93	3.03	1.70
Non-Cash Adjustments To Reconcile Net Income	0.55	3.81	2.45	30	16	2.17	19	140	45	18	30
Changes in Operating Assets and Liabilities, net	-0.83	-0.56	0.30	-3.22	-5.24	-2.58	-28	-25	-0.79	2.57	-8.84
Net Cash From Investing Activities	4.24	0.39	-0.14	-6.50	-27	-25	-13	-58	18	58	-72
Net Cash From Continuing Investing Activities	4.24	0.39	-0.14	-6.50	-27	-25	-13	-58	18	58	-72
Purchase of Property, Plant & Equipment	-1.42	-1.26	-0.14	-0.50	-0.68	-1.96	-8.39	-10	-6.38	-3.23	-9.48
Acquisitions	-	-	-	-6.00	-23	-15	-	0.00	0.00	-0.30	-10
Purchase of Investments	-1.41	-	0.00	0.00	-1.00	0.00	0.00	-53	-27	-18	-114
Divestitures	-	-	-	-	1.25	0.00	1.56	0.00	0.00	73	24
Sale and/or Maturity of Investments	7.07	1.65	-	-	-	0.00	0.00	8.92	56	22	42
Other Investing Activities, net	-	-	-	0.00	-3.16	-7.84	-6.37	-3.54	-4.86	-15	-2.89
Net Cash From Financing Activities	0.37	3.17	4.80	28	1.60	102	-2.78	16	11	-6.78	-11
Net Cash From Continuing Financing Activities	0.37	3.17	4.80	28	1.60	96	-2.78	16	11	-6.78	-11
Repayment of Debt	0.00	0.00	-0.01	-0.07	-0.16	-2.23	-32	-2.50	-0.43	-6.68	-9.97
Issuance of Common Equity	-	-	0.00	20	0.00	100	0.00	0.00	10	0.00	0.00
Other Financing Activities, net	0.37	0.28	3.97	13	1.76	1.03	0.39	-1.05	0.78	-0.10	-0.96
Other Net Changes in Cash	-	-	-	-	-	-	-	-0.11	0.04	0.00	0.00
Cash Interest Paid	-	-	-	-	0.00	0.00	0.45	0.59	1.93	1.61	0.76

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	2.28	-2.11	16	-5.65	-7.68	2.08	71	-28	-35	-2.42	3.56
Net Cash From Operating Activities	-7.72	-4.38	2.31	-4.48	6.46	4.80	1.65	1.73	7.37	6.10	4.92
Net Cash From Continuing Operating Activities	-7.72	-4.38	2.31	-4.48	6.46	4.80	1.65	1.73	7.37	6.10	4.92
Net Income / (Loss) Continuing Operations	-10	-29	-15	-10	-21	-1.70	12	-0.45	-16	0.62	11
Consolidated Net Income / (Loss)	-10	-29	-15	-10	-21	-1.70	12	-0.45	-16	0.62	11
Depreciation Expense	2.00	1.92	1.47	1.36	1.45	1.41	0.94	0.68	0.67	0.64	0.26
Amortization Expense	1.10	1.05	0.70	0.73	0.77	0.82	0.70	0.60	0.51	0.47	0.12
Non-Cash Adjustments To Reconcile Net Income	-0.10	25	11	8.68	22	4.46	-15	4.83	22	4.35	-1.72
Changes in Operating Assets and Liabilities, net	-0.52	-3.42	3.68	-5.03	3.13	-0.18	2.18	-3.94	-0.11	0.03	-4.82
Net Cash From Investing Activities	9.29	1.66	3.96	-0.22	-13	-1.68	74	-27	-40	-5.97	1.14
Net Cash From Continuing Investing Activities	9.29	1.66	3.96	-0.22	-13	-1.68	74	-27	-40	-5.97	1.14
Purchase of Property, Plant & Equipment	-0.61	-1.50	-0.98	-0.36	-1.00	-1.11	-0.76	-0.18	-1.74	-3.30	-4.26
Purchase of Investments	-7.53	-6.96	-4.41	-6.37	-4.34	-5.30	-2.40	-30	-34	-13	-37
Sale and/or Maturity of Investments	19	11	11	6.97	6.07	5.17	3.71	3.57	6.57	13	19
Other Investing Activities, net	-1.55	-0.90	-1.40	-0.46	-14	-0.43	-0.04	-0.25	-0.16	-2.37	-0.10
Net Cash From Financing Activities	0.70	0.61	9.84	-0.95	-0.70	-1.04	-4.09	-2.99	-2.88	-2.56	-2.50
Net Cash From Continuing Financing Activities	0.70	0.61	9.84	-0.95	-0.70	-1.04	-4.09	-2.99	-2.88	-2.56	-2.50
Repayment of Debt	-0.15	-0.33	0.17	-0.23	-0.28	-2.70	-3.48	-2.49	-2.49	-2.49	-2.50
Cash Interest Paid	0.44	0.46	0.53	0.45	0.38	0.41	0.37	0.27	0.22	0.16	0.12

This table presents BioLife Solutions' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	12	7.93	12	45	93	235	554	450	413	399	406
Total Current Assets	6.97	4.63	9.93	38	24	115	126	138	121	149	137
Cash & Equivalents	2.17	1.41	6.66	31	6.45	90	70	19	28	92	33
Short-Term Investments	1.65	-	-	-	-	-	0.00	43	16	9.20	56
Accounts Receivable	0.93	1.19	1.02	3.05	5.35	8.01	23	34	7.90	8.48	7.95
Inventories, net	1.83	1.76	1.85	3.51	11	12	28	35	27	29	30
Prepaid Expenses	0.38	0.27	0.40	0.35	1.35	4.65	4.66	6.88	4.67	5.95	9.53
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	37	4.58	0.00
Plant, Property, & Equipment, net	1.45	1.19	1.11	1.32	5.57	10	18	24	5.69	5.97	15
Total Noncurrent Assets	3.95	2.11	1.11	6.58	63	110	411	288	286	245	255
Long-Term Investments	-	-	1.07	6.55	2.50	5.87	4.37	6.40	5.62	1.00	31
Goodwill	-	-	-	0.00	34	58	225	225	212	209	209
Intangible Assets	2.22	-	-	0.00	22	31	152	32	12	5.57	4.26
Other Noncurrent Operating Assets	1.73	2.11	0.04	0.04	5.01	15	29	25	14	16	11
Other Noncurrent Nonoperating Assets	-	-	-	-	-	-	-	-	43	14	0.00
Total Liabilities & Shareholders' Equity	12	7.93	12	45	93	235	554	450	413	399	406
Total Liabilities	2.51	4.76	2.05	31	49	30	76	86	75	51	34
Total Current Liabilities	1.73	1.13	1.51	1.94	7.67	16	43	45	42	33	23
Short-Term Debt	-	-	-	0.00	0.38	3.25	5.99	3.95	6.29	11	5.00
Accounts Payable	1.03	0.71	0.69	0.72	3.12	3.67	15	15	2.27	3.36	1.49
Accrued Expenses	0.15	0.12	0.20	1.22	3.37	4.76	16	18	9.12	12	12
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	2.59	4.15	4.40	4.23	2.28
Other Current Liabilities	-	-	-	0.00	0.80	3.90	2.91	3.02	1.29	1.46	2.24
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	19	0.62	0.00
Total Noncurrent Liabilities	0.78	3.63	0.54	29	42	14	34	41	33	18	11
Long-Term Debt	-	2.84	-	-	-	0.66	6.35	24	18	5.00	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	0.00	5.49	0.25	0.11	0.12	0.19
Other Noncurrent Operating Liabilities	0.00	0.10	0.05	29	42	13	21	17	8.70	13	11
Other Noncurrent Nonoperating Liabilities	-	-	-	-	-	-	-	-	6.50	0.08	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	9.86	3.17	10	15	43	205	478	364	338	349	372
Total Preferred & Common Equity	8.51	3.17	10	15	43	205	478	364	338	349	372
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	8.51	3.17	10	15	43	205	478	364	338	349	372
Common Stock	73	74	84	113	144	303	585	612	653	684	711
Retained Earnings	-64	-71	-74	-98	-100	-97	-107	-247	-315	-335	-340
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	0.00	-0.28	-0.68	-0.35	0.02	0.13

This table presents BioLife Solutions' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	470	488	446	433	411	402	375	382	395	387	392
Total Current Assets	118	136	133	120	117	112	88	89	131	125	127
Cash & Equivalents	24	27	19	21	19	30	22	24	67	32	29
Short-Term Investments	23	35	36	25	22	16	12	10	22	50	49
Accounts Receivable	31	32	30	27	25	19	18	18	9.17	10	11
Inventories, net	33	34	41	39	43	43	32	32	28	28	28
Prepaid Expenses	6.89	8.04	6.20	7.99	7.85	4.41	3.48	4.91	5.82	5.92	8.95
Plant, Property, & Equipment, net	19	22	26	26	21	21	17	18	6.61	7.67	11
Total Noncurrent Assets	333	330	288	287	273	269	270	275	257	254	254
Long-Term Investments	4.86	5.07	7.09	6.91	6.23	5.07	3.68	5.88	20	18	19
Goodwill	225	225	225	225	225	225	225	225	212	212	212
Intangible Assets	77	74	31	29	22	20	19	18	8.86	8.15	7.45
Other Noncurrent Operating Assets	27	25	25	25	20	19	22	25	16	15	15
Total Liabilities & Shareholders' Equity	470	488	446	433	411	402	375	382	395	387	392
Total Liabilities	58	79	88	81	79	68	54	56	43	40	38
Total Current Liabilities	33	37	47	40	43	39	31	32	28	28	27
Short-Term Debt	2.97	4.74	4.55	2.02	5.09	8.62	11	12	10	10	7.49
Accounts Payable	12	13	16	11	12	4.98	4.21	3.84	3.30	3.21	2.89
Accrued Expenses	16	16	20	19	17	17	8.31	8.64	8.21	9.31	11
Current Deferred & Payable Income Tax Liabilities	-	-	4.59	4.99	5.47	5.40	4.86	4.35	3.93	3.58	3.68
Other Current Liabilities	2.89	2.93	3.07	3.34	3.30	3.00	2.82	3.11	1.84	2.17	2.18
Total Noncurrent Liabilities	25	42	41	41	37	30	23	24	15	12	11
Long-Term Debt	6.19	24	24	24	21	16	10	7.82	2.50	0.00	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	1.15	0.39	0.26	0.26	0.29	0.19	0.19	0.10	0.13	0.18	0.19
Other Noncurrent Operating Liabilities	17	18	17	16	14	13	11	15	12	12	11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	412	408	358	352	332	333	321	325	353	347	354
Total Preferred & Common Equity	412	408	358	352	332	333	321	325	353	347	354
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	412	408	358	352	332	333	321	325	353	347	354
Common Stock	598	604	619	623	633	659	668	673	688	698	704
Retained Earnings	-185	-195	-261	-271	-300	-325	-346	-348	-336	-351	-351
Accumulated Other Comprehensive Income / (Loss)	-0.90	-1.26	-0.53	-0.50	-0.66	-0.57	-0.56	-0.21	0.03	0.07	0.13

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.17%	27.57%	33.97%	79.11%	38.64%	75.69%	147.79%	-36.02%	-0.50%	8.44%	28.89%
EBITDA Growth	-67.94%	6.40%	81.86%	-2,949.12%	159.33%	-83.14%	-1,006.34%	149.00%	-155.43%	126.02%	-357.75%
EBIT Growth	-59.93%	2.90%	76.00%	-2,014.18%	151.21%	-120.95%	-1,225.45%	84.97%	-223.55%	61.04%	-271.25%
NOPAT Growth	-60.00%	3.30%	78.23%	446.78%	-106.01%	-2,736.82%	-463.37%	83.15%	-295.75%	69.59%	-270.83%
Net Income Growth	-51.34%	-60.98%	68.72%	-894.23%	93.37%	219.67%	-549.22%	-1,469.43%	51.36%	70.32%	77.23%
EPS Growth	-12.90%	-54.29%	61.11%	-642.86%	94.23%	33.33%	-283.33%	-1,313.04%	52.31%	71.61%	77.27%
Operating Cash Flow Growth	-57.29%	13.01%	113.98%	288.10%	-48.34%	447.82%	-169.12%	-84.80%	-47.24%	167.46%	138.58%
Free Cash Flow Firm Growth	38.47%	64.58%	176.62%	1,725.58%	-309.53%	-42.89%	-298.70%	127.23%	-45.37%	-103.96%	-346.64%
Invested Capital Growth	50.95%	-23.70%	-48.77%	-1,056.89%	254.53%	223.47%	269.06%	-22.46%	-20.20%	-1.19%	4.70%
Revenue Q/Q Growth	2.37%	5.52%	8.73%	13.33%	11.58%	15.44%	23.38%	-50.75%	-43.72%	-42.63%	-3.92%
EBITDA Q/Q Growth	-16.36%	16.42%	19.63%	-1,029.67%	135.34%	-93.09%	-66.71%	111.20%	91.56%	104.30%	23.81%
EBIT Q/Q Growth	-9.12%	13.76%	20.53%	-1,119.70%	130.17%	-108.61%	-51.55%	95.39%	79.34%	85.24%	23.88%
NOPAT Q/Q Growth	-8.66%	13.80%	27.92%	6.74%	-113.90%	-119.91%	-59.07%	94.84%	73.66%	84.37%	17.24%
Net Income Q/Q Growth	-8.83%	-36.82%	54.46%	-1,477.52%	94.82%	-74.51%	-321.32%	-31.44%	33.48%	56.15%	-43.33%
EPS Q/Q Growth	-6.06%	-45.95%	48.78%	-4,000.00%	96.10%	66.67%	0.00%	0.00%	0.00%	56.44%	-66.67%
Operating Cash Flow Q/Q Growth	-13.03%	12.22%	169.86%	-8.49%	-56.69%	96.31%	-194.05%	50.42%	-79.78%	-7.32%	19.42%
Free Cash Flow Firm Q/Q Growth	22.01%	63.73%	-5.87%	-46.39%	1.38%	-34.59%	9.78%	419.61%	1,279.40%	92.59%	-179.01%
Invested Capital Q/Q Growth	9.11%	-34.31%	-46.19%	49.28%	132.20%	52.06%	-1.44%	-12.76%	-17.41%	-16.83%	-2.33%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.15%	58.09%	61.20%	68.51%	68.00%	57.07%	31.09%	61.53%	60.55%	65.25%	64.56%
EBITDA Margin	-72.71%	-53.35%	-7.22%	-122.94%	52.61%	5.05%	-18.47%	14.14%	-7.88%	1.89%	-11.26%
Operating Margin	-77.80%	-58.97%	-9.58%	18.55%	-0.80%	-12.98%	-29.51%	-7.77%	-30.90%	-8.67%	-17.26%
EBIT Margin	-77.46%	-58.96%	-10.56%	-124.65%	46.04%	-5.49%	-29.37%	-6.90%	-22.44%	-8.06%	-15.37%
Profit (Net Income) Margin	-77.46%	-97.74%	-22.82%	-126.66%	-6.05%	4.12%	-7.48%	-183.38%	-89.65%	-24.54%	-4.78%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	51.81%	-154.80%	30.69%	2,883.77%	368.16%	176.67%	38.03%
Interest Burden Percent	100.00%	165.79%	216.07%	101.61%	-25.38%	48.52%	82.95%	92.15%	108.51%	172.27%	81.70%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-70.01%	-63.84%	-21.23%	0.00%	-2.50%	-5.91%	-9.30%	-1.12%	-5.65%	-1.95%	-4.63%
ROIC Less NNEP Spread (ROIC-NNEP)	-48.45%	325.47%	35.19%	0.00%	4.06%	-18.49%	-29.69%	262.62%	79.47%	15.49%	-11.05%
Return on Net Nonoperating Assets (RNNOA)	28.03%	-59.63%	-16.71%	0.00%	-3.20%	7.51%	6.69%	-32.08%	-13.73%	-3.93%	3.36%
Return on Equity (ROE)	-41.99%	-123.47%	-37.94%	-202.27%	-5.71%	1.59%	-2.61%	-33.20%	-19.38%	-5.88%	-1.28%
Cash Return on Invested Capital (CROIC)	-110.62%	-36.95%	43.26%	0.00%	-165.15%	-111.46%	-124.02%	24.17%	16.82%	-0.76%	-9.23%
Operating Return on Assets (OROA)	-35.13%	-47.80%	-11.60%	-85.43%	18.23%	-1.61%	-8.87%	-1.05%	-3.95%	-1.63%	-3.67%
Return on Assets (ROA)	-35.13%	-79.24%	-25.06%	-86.81%	-2.40%	1.21%	-2.26%	-27.84%	-15.76%	-4.97%	-1.14%
Return on Common Equity (ROCE)	-35.84%	-110.67%	-37.94%	-202.27%	-5.71%	1.59%	-2.61%	-33.20%	-19.38%	-5.88%	-1.28%
Return on Equity Simple (ROE_SIMPLE)	-58.71%	-253.98%	-24.92%	-170.89%	-3.81%	0.97%	-1.86%	-38.39%	-20.14%	-5.78%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.51	-3.40	-0.74	2.56	-0.15	-4.37	-25	-4.15	-16	-4.99	-12
NOPAT Margin	-54.46%	-41.28%	-6.71%	12.98%	-0.56%	-9.09%	-20.66%	-5.44%	-21.63%	-6.07%	-12.08%
Net Nonoperating Expense Percent (NNEP)	-21.56%	-389.31%	-56.42%	-122.70%	-6.57%	12.58%	20.39%	-263.74%	-85.12%	-17.44%	6.42%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-1.06%	-4.54%	-1.37%	-3.08%
Cost of Revenue to Revenue	40.86%	41.91%	38.80%	31.49%	32.00%	42.93%	68.91%	38.47%	39.45%	34.75%	35.44%
SG&A Expenses to Revenue	75.50%	55.82%	41.04%	30.14%	32.49%	31.76%	28.26%	43.62%	57.04%	49.29%	47.31%
R&D to Revenue	21.38%	24.66%	10.82%	6.57%	11.57%	13.97%	9.92%	11.37%	15.92%	9.62%	7.86%
Operating Expenses to Revenue	136.94%	117.06%	70.79%	49.96%	68.80%	70.04%	60.60%	69.30%	91.45%	73.92%	81.82%
Earnings before Interest and Taxes (EBIT)	-5.00	-4.85	-1.16	-25	13	-2.64	-35	-5.26	-17	-6.63	-15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.69	-4.39	-0.80	-24	14	2.43	-22	11	-5.98	1.56	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.12	6.55	8.10	15.21	7.62	6.36	3.25	2.14	2.12	3.45	3.13
Price to Tangible Book Value (P/TBV)	4.22	6.55	8.10	15.21	0.00	11.28	15.34	7.25	6.31	9.48	7.32
Price to Revenue (P/Rev)	4.12	2.52	7.42	11.27	12.09	27.16	13.03	10.21	9.43	14.64	12.10
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	658.52	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.99	4.82	31.39	0.00	9.24	10.75	3.58	2.28	2.68	4.36	4.09
Enterprise Value to Revenue (EV/Rev)	3.74	2.70	6.72	9.39	11.78	25.23	12.51	9.67	9.09	13.49	10.90
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	22.39	499.76	0.00	68.36	0.00	713.79	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	25.58	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	72.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	122.40	78.94	265.74	182.61	0.00	0.00	0.00	131.65	52.15
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	49.17	6.74	0.00	0.00	0.00	8.25	14.12	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.90	0.00	0.00	0.01	0.02	0.03	0.08	0.07	0.05	0.01
Long-Term Debt to Equity	0.00	0.90	0.00	0.00	0.00	0.00	0.01	0.07	0.05	0.01	0.00
Financial Leverage	-0.58	-0.18	-0.47	-1.82	-0.79	-0.41	-0.23	-0.12	-0.17	-0.25	-0.30
Leverage Ratio	1.20	1.56	1.51	2.33	2.38	1.32	1.15	1.19	1.23	1.18	1.12
Compound Leverage Factor	1.20	2.58	3.27	2.37	-0.60	0.64	0.96	1.10	1.33	2.04	0.91
Debt to Total Capital	0.00%	47.32%	0.00%	0.00%	0.86%	1.87%	2.57%	7.11%	6.60%	4.37%	1.33%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.86%	1.55%	1.22%	1.01%	1.74%	3.00%	1.33%
Long-Term Debt to Total Capital	0.00%	47.32%	0.00%	0.00%	0.00%	0.32%	1.35%	6.10%	4.86%	1.37%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	13.70%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.30%	52.68%	100.00%	100.00%	99.14%	98.13%	97.43%	92.89%	93.40%	95.63%	98.67%
Debt to EBITDA	0.00	-0.65	0.00	0.00	0.03	1.61	-0.57	2.59	-3.99	10.25	-0.46
Net Debt to EBITDA	0.00	-0.33	0.00	0.00	-0.60	-38.06	2.80	-3.83	4.34	-60.62	10.63
Long-Term Debt to EBITDA	0.00	-0.65	0.00	0.00	0.00	0.27	-0.30	2.22	-2.94	3.21	0.00
Debt to NOPAT	0.00	-0.84	0.00	0.00	-2.45	-0.90	-0.51	-6.72	-1.45	-3.19	-0.43
Net Debt to NOPAT	0.00	-0.42	0.00	0.00	55.66	21.15	2.50	9.95	1.58	18.89	9.91
Long-Term Debt to NOPAT	0.00	-0.84	0.00	0.00	0.00	-0.15	-0.27	-5.77	-1.07	-1.00	0.00
Altman Z-Score	-1.23	-10.41	16.82	0.89	3.47	26.58	12.13	5.04	4.93	13.61	19.83
Noncontrolling Interest Sharing Ratio	14.64%	10.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.04	4.08	6.56	19.37	3.14	7.37	2.95	3.11	2.86	4.54	5.94
Quick Ratio	2.75	2.29	5.08	17.38	1.54	6.32	2.18	2.17	1.23	3.48	4.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-5.55	-1.97	1.51	27	-58	-82	-328	89	49	-1.93	-23
Operating Cash Flow to CapEx	-350.84%	-344.17%	420.14%	469.60%	179.70%	345.02%	-54.81%	-81.73%	-195.86%	261.26%	212.23%
Free Cash Flow to Firm to Interest Expense	0.00	-4.85	4.35	5,499.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-10.68	1.75	469.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-13.78	1.33	369.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.81	1.10	0.69	0.40	0.29	0.30	0.15	0.18	0.20	0.24
Accounts Receivable Turnover	7.04	7.75	9.95	9.71	6.52	7.20	7.63	2.67	3.63	9.64	11.71
Inventory Turnover	1.88	1.92	2.37	2.32	1.21	1.83	4.11	0.93	0.96	1.02	1.15
Fixed Asset Turnover	4.16	6.25	9.61	16.28	7.94	6.13	8.58	3.69	5.17	13.97	9.30
Accounts Payable Turnover	3.50	3.96	6.10	8.81	4.56	6.08	8.82	1.94	3.39	9.78	14.07
Days Sales Outstanding (DSO)	51.81	47.09	36.67	37.59	55.94	50.67	47.82	136.81	100.65	37.87	31.16
Days Inventory Outstanding (DIO)	193.94	190.13	153.85	157.23	301.69	199.54	88.79	393.58	378.56	358.69	316.70
Days Payable Outstanding (DPO)	104.18	92.09	59.83	41.42	79.98	60.03	41.38	188.62	107.57	37.31	25.94
Cash Conversion Cycle (CCC)	141.57	145.13	130.70	153.39	277.65	190.18	95.23	341.77	371.64	359.24	321.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	6.03	4.60	2.36	-23	35	113	416	323	258	255	257
Invested Capital Turnover	1.29	1.55	3.17	-1.95	4.45	0.65	0.45	0.21	0.26	0.32	0.38
Increase / (Decrease) in Invested Capital	2.04	-1.43	-2.25	-25	57	78	304	-94	-65	-3.06	12
Enterprise Value (EV)	24	22	74	185	322	1,213	1,491	737	690	1,110	1,049
Market Capitalization	27	21	82	223	331	1,306	1,552	778	716	1,204	1,164
Book Value per Share	$0.69	$0.25	$0.74	$0.79	$2.12	$6.27	$11.48	$8.52	$7.67	$7.52	$7.72
Tangible Book Value per Share	$0.51	$0.25	$0.74	$0.79	($0.59)	$3.54	$2.43	$2.51	$2.57	$2.74	$3.30
Total Capital	9.86	6.01	10	15	44	209	491	392	362	365	377
Total Debt	0.00	2.84	0.00	0.00	0.38	3.92	13	28	24	16	5.00
Total Long-Term Debt	0.00	2.84	0.00	0.00	0.00	0.67	6.64	24	18	5.00	0.00
Net Debt	-3.82	1.44	-7.73	-37	-8.57	-92	-62	-41	-26	-94	-115
Capital Expenditures (CapEx)	1.42	1.26	0.14	0.50	0.68	1.93	8.38	10	6.38	3.23	9.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.42	2.09	1.76	4.97	10	12	20	35	41	22	30
Debt-free Net Working Capital (DFNWC)	5.25	3.49	8.42	36	17	102	89	98	85	127	119
Net Working Capital (NWC)	5.25	3.49	8.42	36	16	99	83	94	78	116	114
Net Nonoperating Expense (NNE)	1.48	4.65	1.78	28	1.50	-6.35	-16	136	52	15	-7.03
Net Nonoperating Obligations (NNO)	-3.82	1.44	-7.73	-37	-8.57	-92	-62	-41	-80	-94	-115
Total Depreciation and Amortization (D&A)	0.31	0.46	0.37	0.34	1.80	5.07	13	16	11	8.19	3.95
Debt-free, Cash-free Net Working Capital to Revenue	22.06%	25.39%	15.92%	25.16%	37.90%	24.82%	16.37%	46.03%	53.43%	27.22%	30.82%
Debt-free Net Working Capital to Revenue	81.36%	42.48%	76.37%	180.45%	61.46%	212.93%	75.01%	128.31%	111.67%	154.36%	123.25%
Net Working Capital to Revenue	81.36%	42.48%	76.37%	180.45%	60.08%	206.17%	69.98%	123.13%	103.39%	141.06%	118.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.35)	($0.54)	($0.21)	$0.18	($0.09)	$0.09	($0.20)	($3.29)	($1.52)	($0.44)	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	12.45M	13.00M	14.12M	16.26M	19.46M	33.40M	42.09M	42.48M	43.72M	46.07M	47.75M
Adjusted Diluted Earnings per Share	($0.35)	($0.54)	($0.21)	$0.14	($0.09)	($0.03)	($0.20)	($3.29)	($1.52)	($0.44)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	12.45M	13.00M	14.12M	21.63M	19.46M	33.40M	42.09M	43.21M	43.72M	46.07M	48.65M
Adjusted Basic & Diluted Earnings per Share	($0.35)	($0.54)	($0.21)	$0.00	($0.09)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.18M	12.64M	13.26M	18.65M	19.46M	27.31M	38.50M	43.21M	45.30M	47M	48.30M
Normalized Net Operating Profit after Tax (NOPAT)	-3.51	-3.40	-0.74	2.56	0.54	-2.80	-21	-7.47	-18	-4.99	-12
Normalized NOPAT Margin	-54.46%	-41.28%	-6.71%	12.98%	1.97%	-5.82%	-18.01%	-9.80%	-23.65%	-6.07%	-12.08%
Pre Tax Income Margin	-77.46%	-97.74%	-22.82%	-126.66%	-11.68%	-2.66%	-24.36%	-6.36%	-24.35%	-13.89%	-12.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-11.97	-3.36	-4,921.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-8.38	-2.14	512.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-15.08	-3.78	-5,021.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-11.49	-2.55	412.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	-4.21%	-1.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-1.39%	-6.28%	-1.74%	0.00%	312.66%	-1.63%	-0.09%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-27.87%	-42.15%	64.47%	-15.85%	-3.11%	29.69%	42.88%	29.88%	28.94%	31.21%	24.34%
EBITDA Growth	97.19%	-68.39%	-79.97%	25.18%	76.04%	106.23%	-51.61%	117.34%	-1,527.20%	-31.83%	33.85%
EBIT Growth	93.30%	-31.40%	-81.76%	25.19%	47.14%	90.39%	-55.15%	63.35%	-1,313.45%	160.75%	368.33%
NOPAT Growth	86.12%	-31.81%	-81.80%	25.56%	73.70%	89.93%	-54.60%	63.03%	-1,174.35%	73.13%	175.61%
Net Income Growth	86.01%	-182.37%	69.59%	25.47%	-103.15%	94.15%	183.30%	95.62%	23.56%	136.47%	-11.15%
EPS Growth	86.63%	-179.17%	0.00%	31.25%	-95.65%	94.03%	181.82%	95.45%	26.67%	125.00%	-14.81%
Operating Cash Flow Growth	22.17%	-392.71%	-70.59%	-65.01%	183.69%	209.66%	-28.82%	138.59%	14.07%	27.11%	198.85%
Free Cash Flow Firm Growth	193.41%	7.20%	-55.62%	-90.24%	-50.63%	-89.99%	-87.10%	269.20%	92.05%	681.61%	-177.59%
Invested Capital Growth	-11.99%	-15.71%	-20.20%	-4.94%	-6.20%	-1.87%	-1.19%	-16.69%	-15.93%	-14.16%	4.70%
Revenue Q/Q Growth	-22.45%	-19.37%	-162.18%	-26.22%	-10.71%	7.92%	-127.39%	385.97%	6.18%	10.41%	-33.07%
EBITDA Q/Q Growth	80.55%	-506.32%	252.61%	49.42%	93.77%	257.53%	1,086.26%	-98.19%	-9,376.83%	108.54%	124.15%
EBIT Q/Q Growth	61.18%	-197.13%	208.65%	43.73%	72.57%	46.00%	607.24%	-115.01%	-1,370.49%	101.19%	1,196.92%
NOPAT Q/Q Growth	21.88%	-45.61%	252.32%	43.13%	72.40%	44.22%	786.38%	-111.38%	-1,266.42%	99.33%	1,902.83%
Net Income Q/Q Growth	25.63%	-185.64%	48.66%	23.62%	-102.71%	91.78%	831.59%	-103.60%	-3,435.27%	103.92%	1,682.61%
EPS Q/Q Growth	28.13%	-191.30%	50.75%	26.67%	-104.55%	91.11%	775.00%	-103.70%	-3,200.00%	103.03%	2,200.00%
Operating Cash Flow Q/Q Growth	-184.59%	43.26%	152.77%	-293.64%	244.34%	-25.65%	-65.74%	4.98%	326.64%	-17.16%	-19.46%
Free Cash Flow Firm Q/Q Growth	-59.63%	28.05%	72.73%	159.34%	104.32%	-74.03%	122.65%	380.00%	-26.84%	16.82%	-123.38%
Invested Capital Q/Q Growth	0.44%	-4.25%	-17.41%	0.46%	-0.90%	0.17%	-16.83%	0.90%	0.01%	2.28%	-2.33%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	37.71%	50.88%	0.00%	39.59%	52.57%	53.30%	0.00%	65.94%	64.64%	63.85%	63.76%
EBITDA Margin	-6.92%	-52.06%	0.00%	-24.54%	-1.71%	2.50%	0.00%	0.69%	-59.85%	4.63%	15.51%
Operating Margin	-36.35%	-65.65%	0.00%	-31.92%	-9.87%	-5.10%	0.00%	-5.09%	-65.47%	-0.32%	7.18%
EBIT Margin	-17.54%	-64.65%	0.00%	-31.15%	-9.57%	-4.79%	0.00%	-4.66%	-64.50%	0.69%	13.46%
Profit (Net Income) Margin	-34.88%	-123.58%	0.00%	-32.22%	-73.14%	-5.57%	0.00%	-1.87%	-62.30%	2.21%	58.93%
Tax Burden Percent	184.90%	185.68%	-91.45%	101.30%	289.94%	98.38%	165.19%	103.23%	100.80%	88.34%	329.27%
Interest Burden Percent	107.55%	102.95%	98.78%	102.09%	263.59%	118.24%	101.56%	38.92%	95.83%	360.51%	132.94%
Effective Tax Rate	0.00%	0.00%	-1.42%	0.00%	0.00%	0.00%	-1.87%	0.00%	0.00%	11.66%	-5.15%
Return on Invested Capital (ROIC)	-11.11%	-18.16%	0.00%	-9.70%	-2.98%	-1.66%	0.00%	-1.11%	-15.23%	-0.10%	2.89%
ROIC Less NNEP Spread (ROIC-NNEP)	-3.03%	44.82%	0.00%	0.98%	86.23%	1.46%	0.00%	-1.78%	-7.32%	-1.37%	-5.93%
Return on Net Nonoperating Assets (RNNOA)	0.27%	-3.52%	0.00%	-0.08%	-5.38%	-0.09%	0.00%	0.31%	1.16%	0.22%	1.80%
Return on Equity (ROE)	-10.84%	-21.68%	0.00%	-9.78%	-8.37%	-1.74%	0.00%	-0.79%	-14.07%	0.12%	4.69%
Cash Return on Invested Capital (CROIC)	-4.39%	-1.21%	16.82%	-9.84%	-6.80%	-8.44%	-0.76%	16.96%	12.23%	10.30%	-9.23%
Operating Return on Assets (OROA)	-5.90%	-19.39%	0.00%	-10.09%	-3.23%	-1.73%	0.00%	-1.03%	-15.82%	0.18%	3.22%
Return on Assets (ROA)	-11.73%	-37.06%	0.00%	-10.43%	-24.69%	-2.02%	0.00%	-0.41%	-15.28%	0.57%	14.08%
Return on Common Equity (ROCE)	-10.84%	-21.68%	0.00%	-9.78%	-8.37%	-1.74%	0.00%	-0.79%	-14.07%	0.12%	4.69%
Return on Equity Simple (ROE_SIMPLE)	-23.69%	-30.79%	0.00%	-18.88%	-22.85%	-14.14%	0.00%	-2.95%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.44	-11	16	-7.09	-1.96	-1.09	7.49	-0.85	-12	-0.08	1.42
NOPAT Margin	-25.45%	-45.95%	0.00%	-22.35%	-6.91%	-3.57%	0.00%	-3.56%	-45.83%	-0.28%	7.55%
Net Nonoperating Expense Percent (NNEP)	-8.08%	-62.98%	-51.90%	-10.68%	-89.22%	-3.11%	5.70%	0.67%	-7.90%	1.27%	8.82%
Return On Investment Capital (ROIC_SIMPLE)	-	-	4.56%	-	-	-	2.05%	-0.23%	-3.26%	-0.02%	0.38%
Cost of Revenue to Revenue	62.29%	49.12%	0.00%	60.41%	47.43%	46.70%	0.00%	34.06%	35.36%	36.15%	36.24%
SG&A Expenses to Revenue	46.31%	45.87%	0.00%	40.77%	38.46%	37.13%	0.00%	48.04%	44.83%	43.02%	56.16%
R&D to Revenue	12.97%	15.86%	0.00%	11.14%	8.41%	6.71%	0.00%	9.21%	10.70%	9.65%	-0.35%
Operating Expenses to Revenue	74.06%	116.53%	0.00%	71.51%	62.44%	58.40%	0.00%	71.02%	130.11%	64.17%	56.59%
Earnings before Interest and Taxes (EBIT)	-5.13	-15	17	-9.88	-2.71	-1.46	7.43	-1.12	-16	0.20	2.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.02	-12	19	-7.79	-0.49	0.76	9.06	0.16	-15	1.30	2.91
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.73	1.81	2.12	2.52	3.07	3.55	3.45	3.04	2.95	3.45	3.13
Price to Tangible Book Value (P/TBV)	9.78	7.05	6.31	9.50	12.75	14.04	9.48	8.17	8.09	9.12	7.32
Price to Revenue (P/Rev)	6.32	4.46	9.43	6.12	7.23	8.06	14.64	12.23	10.96	12.20	12.10
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.87	1.86	2.68	2.64	3.18	3.71	4.36	3.81	3.64	4.30	4.09
Enterprise Value to Revenue (EV/Rev)	6.15	4.31	9.09	5.94	7.12	7.92	13.49	11.14	10.00	11.30	10.90
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	713.79	366.90	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	124.88	131.65	66.82	60.11	67.15	52.15
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	14.12	0.00	0.00	0.00	0.00	20.40	27.15	38.60	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.08	0.08	0.07	0.08	0.07	0.06	0.05	0.04	0.03	0.02	0.01
Long-Term Debt to Equity	0.07	0.07	0.05	0.05	0.04	0.03	0.01	0.01	0.00	0.00	0.00
Financial Leverage	-0.09	-0.08	-0.17	-0.08	-0.06	-0.06	-0.25	-0.18	-0.16	-0.16	-0.30
Leverage Ratio	1.18	1.21	1.23	1.23	1.20	1.21	1.18	1.16	1.14	1.14	1.12
Compound Leverage Factor	1.27	1.25	1.21	1.25	3.16	1.43	1.20	0.45	1.09	4.11	1.49
Debt to Total Capital	7.10%	7.59%	6.60%	7.08%	6.42%	6.05%	4.37%	3.54%	2.81%	2.07%	1.33%
Short-Term Debt to Total Capital	0.53%	1.42%	1.74%	2.40%	3.09%	3.53%	3.00%	2.86%	2.81%	2.07%	1.33%
Long-Term Debt to Total Capital	6.57%	6.18%	4.86%	4.67%	3.33%	2.52%	1.37%	0.68%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	92.90%	92.41%	93.40%	92.92%	93.58%	93.95%	95.63%	96.46%	97.19%	97.93%	98.67%
Debt to EBITDA	-0.41	-0.39	-3.99	-0.50	-0.45	-0.58	10.25	4.86	-0.74	-0.53	-0.46
Net Debt to EBITDA	0.40	0.28	4.34	0.49	0.32	0.53	-60.62	-35.90	6.62	6.39	10.63
Long-Term Debt to EBITDA	-0.38	-0.31	-2.94	-0.33	-0.23	-0.24	3.21	0.94	0.00	0.00	0.00
Debt to NOPAT	-0.45	-0.44	-1.45	-0.54	-0.53	-0.66	-3.19	-3.66	-0.70	-0.53	-0.43
Net Debt to NOPAT	0.44	0.32	1.58	0.53	0.38	0.60	18.89	27.06	6.32	6.47	9.91
Long-Term Debt to NOPAT	-0.42	-0.36	-1.07	-0.36	-0.27	-0.27	-1.00	-0.71	0.00	0.00	0.00
Altman Z-Score	6.77	3.95	5.20	6.74	10.29	11.60	13.73	14.49	14.47	18.43	19.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.04	2.74	2.86	2.89	2.86	2.78	4.54	4.73	4.43	4.66	5.94
Quick Ratio	1.85	1.54	1.23	1.65	1.69	1.62	3.48	3.53	3.24	3.31	4.22
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	37	47	82	8.93	18	4.74	11	51	37	43	-10
Operating Cash Flow to CapEx	-1,267.32%	-292.71%	235.58%	-1,257.02%	649.15%	431.06%	215.88%	986.86%	422.72%	184.86%	115.45%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.30	0.18	0.32	0.34	0.36	0.20	0.22	0.25	0.26	0.24
Accounts Receivable Turnover	5.23	4.73	3.63	5.61	6.07	6.75	9.64	6.33	6.65	6.96	11.71
Inventory Turnover	2.74	2.17	0.96	2.17	2.43	2.38	1.02	0.86	1.10	1.19	1.15
Fixed Asset Turnover	6.80	6.31	5.17	5.82	6.37	7.41	13.97	6.35	7.50	6.95	9.30
Accounts Payable Turnover	8.93	6.67	3.39	8.97	11.71	11.37	9.78	7.38	8.90	10.63	14.07
Days Sales Outstanding (DSO)	69.80	77.18	100.65	65.02	60.11	54.06	37.87	57.69	54.91	52.41	31.16
Days Inventory Outstanding (DIO)	133.44	168.03	378.56	168.07	149.93	153.26	358.69	424.08	332.58	306.13	316.70
Days Payable Outstanding (DPO)	40.89	54.74	107.57	40.67	31.17	32.10	37.31	49.48	41.01	34.32	25.94
Cash Conversion Cycle (CCC)	162.35	190.46	371.64	192.41	178.88	175.23	359.24	432.29	346.48	324.21	321.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	326	312	258	308	306	306	255	257	257	263	257
Invested Capital Turnover	0.44	0.40	0.26	0.43	0.43	0.46	0.32	0.31	0.33	0.35	0.38
Increase / (Decrease) in Invested Capital	-44	-58	-65	-16	-20	-5.83	-3.06	-51	-49	-43	12
Enterprise Value (EV)	934	581	690	815	971	1,136	1,110	978	934	1,131	1,049
Market Capitalization	960	601	716	840	986	1,155	1,204	1,073	1,024	1,222	1,164
Book Value per Share	$8.10	$7.63	$7.67	$7.36	$6.98	$7.05	$7.52	$7.50	$7.30	$7.38	$7.72
Tangible Book Value per Share	$2.26	$1.96	$2.57	$1.95	$1.68	$1.78	$2.74	$2.80	$2.66	$2.80	$3.30
Total Capital	379	359	362	359	344	346	365	366	357	361	377
Total Debt	27	27	24	25	22	21	16	13	10	7.49	5.00
Total Long-Term Debt	25	22	18	17	11	8.74	5.00	2.50	0.00	0.00	0.00
Net Debt	-26	-20	-26	-25	-16	-19	-94	-96	-90	-91	-115
Capital Expenditures (CapEx)	0.61	1.50	0.98	0.36	1.00	1.11	0.76	0.18	1.74	3.30	4.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	36	38	41	36	34	35	22	25	25	28	30
Debt-free Net Working Capital (DFNWC)	83	79	85	82	68	69	127	114	107	107	119
Net Working Capital (NWC)	81	74	78	73	57	57	116	103	97	99	114
Net Nonoperating Expense (NNE)	2.76	18	31	3.13	19	0.61	-4.97	-0.40	4.19	-0.70	-9.65
Net Nonoperating Obligations (NNO)	-26	-20	-80	-25	-16	-19	-94	-96	-90	-91	-115
Total Depreciation and Amortization (D&A)	3.11	2.97	2.17	2.10	2.23	2.23	1.64	1.28	1.18	1.11	0.39
Debt-free, Cash-free Net Working Capital to Revenue	23.99%	28.36%	53.43%	26.48%	24.80%	24.46%	27.22%	28.80%	27.18%	27.92%	30.82%
Debt-free Net Working Capital to Revenue	54.46%	58.83%	111.67%	59.48%	49.85%	48.44%	154.36%	129.73%	114.66%	106.76%	123.25%
Net Working Capital to Revenue	53.13%	55.06%	103.39%	53.20%	42.07%	39.90%	141.06%	117.83%	103.91%	99.28%	118.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27	($0.01)	($0.33)	$0.01	$0.24
Adjusted Weighted Average Basic Shares Outstanding	43.44M	43.57M	43.72M	45.43M	25.29M	46.18M	46.07M	46.69M	31.96M	47.93M	47.75M
Adjusted Diluted Earnings per Share	($0.23)	($0.67)	($0.33)	($0.22)	($0.45)	($0.04)	$0.27	($0.01)	($0.33)	$0.01	$0.23
Adjusted Weighted Average Diluted Shares Outstanding	43.44M	43.57M	43.72M	45.43M	46.00M	46.18M	46.07M	47.13M	31.96M	48.72M	48.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	43.49M	44.03M	45.30M	46.03M	46.14M	46.39M	47M	47.56M	47.91M	48.15M	48.30M
Normalized Net Operating Profit after Tax (NOPAT)	-8.08	-6.12	11	-6.92	-1.96	-1.09	5.15	-0.85	-12	-0.08	0.94
Normalized NOPAT Margin	-27.64%	-25.97%	0.00%	-21.82%	-6.91%	-3.57%	0.00%	-3.56%	-45.83%	-0.28%	5.02%
Pre Tax Income Margin	-18.87%	-66.56%	0.00%	-31.80%	-25.23%	-5.66%	0.00%	-1.81%	-61.81%	2.50%	17.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, data-driven read on BioLife Solutions (BLFS) using the last four years of quarterly statements. The focus is on cash flow, liquidity, earnings volatility, and balance-sheet posture.

Strong operating cash flow recently: Net Cash From Continuing Operating Activities was about $6.10 million in Q3 2025 and $4.92 million in Q4 2025, supporting liquidity and funding optionality. (Q3 2025: $6,104,000; Q4 2025: $4,916,000)
No long-term debt on the balance sheet: Long-Term Debt is shown as $0.0 in Q3 2025, reducing leverage risk.
Solid liquidity position: Cash & Equivalents plus Short-Term Investments totaled about $78.95 million in Q3 2025 (Cash $29.48m + Short-Term Investments $49.47m), with Total Current Assets around $126.57 million.
Healthy gross margin in Q4 2025: Total Gross Profit $11.978 million on Revenue $18.785 million, roughly 63.8% gross margin.

High goodwill and intangible asset levels on the balance sheet: Goodwill about $212.304 million and Intangible Assets about $7.45 million in Q3 2025, signaling an acquisitions-heavy asset base with potential impairment risks if growth slows.
Discontinued operations contributed to Q4 2025 net income: $7.535 million from discontinued operations; this boosts quarterly earnings but may not reflect ongoing operations.
Earnings from continuing operations have been volatile across recent quarters: Q1 2025 continuing net income about -$4.48 million; Q2 2025 about -$15.84 million; Q3 2025 about +$0.62 million; Q4 2025 about +$3.54 million (approx for continuing ops in Q4).

Big impairment hit in 2025 Q2: Impairment expense of $69.9 million weighed on profitability.
Material investing cash outflows in 2025: notable cash outlays for investing activities (e.g., around $36.7 million invested in Q4 2025; about $33.98 million invested in Q2 2025), pressuring free cash flow.
Occasional continued-op earnings weakness: several quarters show negative net income from continuing operations (e.g., Q1 2025 around -$4.48 million; Q2 2025 around -$15.84 million), highlighting ongoing profitability challenges outside one-off items.

05/07/26 06:19 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About BioLife Solutions' Financials

When does BioLife Solutions' financial year end?

According to the most recent income statement we have on file, BioLife Solutions' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has BioLife Solutions' net income changed over the last 10 years?

BioLife Solutions' net income appears to be on an upward trend, with a most recent value of -$4.60 million in 2025, falling from -$5.00 million in 2015. The previous period was -$20.18 million in 2024. Check out BioLife Solutions' forecast to explore projected trends and price targets.

What is BioLife Solutions' operating income?

BioLife Solutions' total operating income in 2025 was -$16.60 million, based on the following breakdown:

Total Gross Profit: $62.12 million
Total Operating Expenses: $78.72 million

How has BioLife Solutions' revenue changed over the last 10 years?

Over the last 10 years, BioLife Solutions' total revenue changed from $6.45 million in 2015 to $96.21 million in 2025, a change of 1,391.9%.

How much debt does BioLife Solutions have?

BioLife Solutions' total liabilities were at $34.00 million at the end of 2025, a 32.8% decrease from 2024, and a 1,254.3% increase since 2015.

How much cash does BioLife Solutions have?

In the past 10 years, BioLife Solutions' cash and equivalents has ranged from $1.41 million in 2016 to $91.54 million in 2024, and is currently $33.04 million as of their latest financial filing in 2025.

How has BioLife Solutions' book value per share changed over the last 10 years?

Over the last 10 years, BioLife Solutions' book value per share changed from 0.69 in 2015 to 7.72 in 2025, a change of 1,011.5%.

Related Companies

Financial statements for NASDAQ:BLFS last updated on 3/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About BioLife Solutions' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Financials

Annual Income Statements for BioLife Solutions

Quarterly Income Statements for BioLife Solutions

Annual Cash Flow Statements for BioLife Solutions

Quarterly Cash Flow Statements for BioLife Solutions

Annual Balance Sheets for BioLife Solutions

Quarterly Balance Sheets for BioLife Solutions

Annual Metrics And Ratios for BioLife Solutions

Quarterly Metrics And Ratios for BioLife Solutions

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About BioLife Solutions' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools